Anti-HER2 antibody-medication conjugate effective as first-line therapy for advanced breast cancer: Research A new type of breasts cancer treatment shows encouraging activity as a first-line therapy in HER2-positive metastatic disease, researchers reported at the 35th Congress of the European Society for Medical Oncology in Milan, Italy nizagara100.com . Principal investigator Edith Perez, MD, Mayo Clinic in Florida, presented the outcomes of the 1st ever randomized trial of trastuzumab-DM1 as a first-line treatment for metastatic breast cancer.
Related StoriesShared decision making between doctors and individuals useful in fight antibiotic resistanceTackling MRSA with bacteriophageUnlocking the genes behind antibiotic resistance: an interview with Professor RomesbergEvery 5 minutes someone in the united kingdom includes a stroke and stroke currently accounts for almost 10 percent of deaths worldwide, claiming more lives than HIV/Helps. Throughout a stroke, a clot prevents blood flow to parts of the mind, which can have wide ranging long-term and short-term implications. This study recorded the result of intravenous minocycline in both isolated neurons and pet versions after a stroke have been experimentally induced.